SLC7A11 and obesity disorder: Combining xCT inhibitors with a CSE inhibitor could potentially provide a rapid and innovative solution to combat obesity and other pathologies associated with high cysteine levels, e.g. cystinuria and tumors that require cysteine for growth and progression.